Efficacy and safety of secukinumab in moderate to severe plaque psoriasis

被引：0
|
作者：
Aparicio Rubio, Celia [1 ]
Monteagudo Santolaya, Emilio [1 ]
Cornejo Uixeda, Silvia [1 ]
Prieto Castello, Manuel [1 ]
Antonino de la Camara, Gonzalo [1 ]
Quintana Vergara, Belen [1 ]
Sanchez Alcaraz, Agustin [1 ]
机构：
[1] Hosp Univ Ribera, Alzira, Spain
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY | 2018年 / 40卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PT019
引用
收藏
页码：299 / 299
页数：1
相关论文
共 50 条
  • [21] Secukinumab demonstrates sustained efficacy in moderate to severe plaque psoriasis across disease severity subgroups
    Spelman, L.
    Blauvelt, A.
    Loffler, J.
    Papavassilis, C.
    Fox, T.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 74 - 74
  • [22] Secukinumab demonstrates sustained efficacy in moderate to severe plaque psoriasis across disease severity subgroups
    Spelman, Lynda
    Blauvelt, Andrew
    Loeffler, Juergen
    Papavassilis, Charis
    Fox, Todd
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB248 - AB248
  • [23] Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis
    Pan, Ran
    Wang, Xiaolun
    Shu, Min
    Das, Jaydeep
    Kalra, Manik
    Wang, Zhidong
    CHINESE MEDICAL JOURNAL, 2022, 135 (01) : 11 - 19
  • [24] Real world data with secukinumab for moderate-to-severe plaque psoriasis: Evaluation of safety, efficacy and drug survival in 50 patients
    Gkini, Maria-Angeliki
    Bewley, Anthony
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB114 - AB114
  • [25] Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis
    Cai Lin
    Zhang Jian-Zhong
    Yao Xu
    Gu Jun
    Liu Quan-Zhong
    Zheng Min
    Zhang Shi-Fa
    Xu Jin-Hua
    Li Cheng-Xin
    Cheng Hao
    Guo Qing
    Pan Wei-Li
    Li Shen-Qiu
    Li Ruo-Yu
    Guo Zai-Pei
    Song Zhi-Qi
    Li Shan-Shan
    Dong Xiu-Qin
    Wang Linda
    Fu Rong
    Regnault Pascaline
    Charef Pascal
    Mazur Rafal
    Patekar Manmath
    中华医学杂志英文版, 2020, 133 (22) : 2665 - 2673
  • [26] Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis
    Cai, Lin
    Zhang, Jian-Zhong
    Yao, Xu
    Gu, Jun
    Liu, Quan-Zhong
    Zheng, Min
    Zhang, Shi-Fa
    Xu, Jin-Hua
    Li, Cheng-Xin
    Cheng, Hao
    Guo, Qing
    Pan, Wei-Li
    Li, Shen-Qiu
    Li, Ruo-Yu
    Guo, Zai-Pei
    Song, Zhi-Qi
    Li, Shan-Shan
    Dong, Xiu-Qin
    Wang, Linda
    Fu, Rong
    Regnault, Pascaline
    Charef, Pascal
    Mazur, Rafal
    Patekar, Manmath
    CHINESE MEDICAL JOURNAL, 2020, 133 (22) : 2665 - 2673
  • [27] Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis
    Wong, Ian T. Y.
    Shojania, Kam
    Dutz, Jan
    Tsao, Nicole W.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (02) : 153 - 166
  • [28] Secukinumab efficacy and safety in subjects with moderate to severe plaque psoriasis: Results from the Judging the efficacy of secUkinumab in patients with psoriasis using autoiNjector: a Clinical Trial evalUating treatment REsults trial (JUNCTURE)
    Blauvelt, Andrew
    Gottlieb, Alice
    Prinz, Jorg
    Pathan, Rashidkhan
    Cooper, Simon
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB185 - AB185
  • [29] Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis
    Egeberg, Alexander
    Bryld, Lars Erik
    Skov, Lone
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (01) : 173 - 178
  • [30] Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis
    Pinter, A.
    Gerdes, S.
    Hacker, E.
    Reinhardt, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 114 - 115
12345